A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
Sanofi
Amgen
Celldex Therapeutics
Seagen Inc.
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Novartis
Merck Sharp & Dohme LLC